Drug Database
MM

MMR + varicella zoster vaccine (MMRV zoster vaccine)

✓ Approved

GSK · Vaccine · Vaccine

What is MMR + varicella zoster vaccine?

MMR + varicella zoster vaccine is a vaccine developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NamesMMRV zoster vaccine
CompanyGSK
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved

Therapeutic Indications

MMR + varicella zoster vaccine is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved
Infections and infestationsMeasles✓ Approved
Infections and infestationsVaricella zoster virus infection✓ Approved

Related Research Articles

PubMedJournal of virology2026-11-11

A human sensory neuron model for varicella-zoster virus latency and reactivation in vitro.

Havelaar Alexander C AC, Flot Joseph S JS, Fukuda Saori S, de Jong Anja W M AWM et al.

Varicella-zoster virus (VZV) is a ubiquitous human neurotropic alphaherpesvirus that establishes lifelong latency in sensory ganglionic neurons. Subsequent viral reactivation causes herpes zoster, a morbid disease often complicated by neuropathic pain. Mechanisms underlying VZV latency and reactivation are not understood, mostly due to the lack of permissive animal models and challenges of current in vitro latency modeling. Here, we evaluated HD10.6 cells, a simplified and easily expandable human sensory neuron line to model VZV latency and reactivation. Differentiated HD10.6 (dHD10.6) neurons supported productive VZV infection, viral DNA replication, production of infectious progeny, and viral spread in cultures. VZV infection was associated with limited cytopathic effects and ultrastructural changes. Infecting dHD10.6 neurons with cell-free VZV in the presence of antivirals resulted in a quiescent-persistent state, characterized by persistent VZV genomes with restricted VZV gene expression and absence of infectious virus. Importantly, VZV could be reactivated by treatment with capsaicin, as evidenced by increased lytic viral transcription and virus spread. In conclusion, this study establishes human HD10.6 neurons as a novel and expandable in vitro model for studying VZV latency and reactivation to identify virus and host factors governing latency that may serve as therapeutic targets to restrict VZV reactivation.IMPORTANCEMost individuals carry latent varicella-zoster virus (VZV) in their dorsal root ganglia (DRG), which can reactivate to cause shingles and chronic pain. The mechanisms by which VZV establishes latency and triggers of reactivation are incompletely understood. Current platforms for the study of VZV latency do not easily support functional experiments (ganglia) or are difficult to expand and complicated by mixed neuronal populations (stem cell-derived neurons). Here, we demonstrate that differentiated HD10.6 cells derived from immortalized human DRG-derived neurons provide a clonal and easy-to-expand platform for studying lytic, latent, and reactivated VZV infection in sensory neurons. We propose that the HD10.6 platform could provide the basis to conduct studies on the viral latent state that have hitherto not been possible.

PubMedFrontiers in medicine2026-11-11

Herpes zoster-induced critical rhabdomyolysis with secondary hypothyroidism: a case report.

Lv Xiangkang X, Zhang Bin B, Yang Wei W, Lu Xiao X

Primary varicella-zoster virus (VZV) reactivation causes herpes zoster (HZ), typically presenting with dermatomal rash and neuropathic pain. Rhabdomyolysis as a systemic complication of HZ is extremely rare, and its underlying pathogenesis and optimal management remain poorly characterized, especially in elderly patients. Here we report a 63-year-old female who presented with fever, generalized myalgia, and oliguria, with serum creatine kinase (CK) rapidly escalating from 4,383 U/L to a peak of 186,383 U/L. Further investigation revealed a preceding history of lumbar herpes zoster two weeks prior, accompanied by virus-induced secondary hypothyroidism. Muscle biopsy confirmed extensive myofiber necrosis without inflammatory infiltration, consistent with non-inflammatory rhabdomyolysis. The patient developed acute kidney injury, hepatic dysfunction, and respiratory failure, and was managed with multidisciplinary intensive care including mechanical ventilation, 9 days of continuous renal replacement therapy, glucocorticoid anti-inflammatory therapy, and levothyroxine replacement. After 12 days of treatment, CK decreased to 3,381 U/L with significant recovery of multiorgan function, and the patient was transferred out of the intensive care unit. This case highlights that HZ can trigger life-threatening rhabdomyolysis, possibly via VZV-mediated immune dysregulation and secondary hypothyroidism. Detailed history taking, early CK screening, and multidisciplinary organ support are critical to improve outcomes in this rare but severe condition.

PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PubMedHealth communication2026-11-11

Spiritual Health Locus of Control and COVID-19 Booster Intentions Among Hispanic Americans: A Culturally Grounded Extension of the Extended Parallel Process Model.

Kim Joon J, Jun Jungmi J, Zambrano Rodriguez Viviana Carolina VC

Declining uptake of COVID-19 boosters poses significant public health concerns. Hispanic Americans, who have experienced disproportionate pandemic impacts, report lower uptake of updated boosters than non-Hispanic White adults, partly attributable to vaccine hesitancy. Although religiosity plays a central role in Hispanic communities, little is known about how spiritually grounded beliefs shape cognitive and emotional responses to vaccination. This study integrates the extended parallel process model (EPPM) with spiritual health locus of control (SHLOC) to examine how exposure to faith-based and governmental vaccine information influences booster intention through spiritually grounded efficacy appraisals. Using an online survey of Hispanic American adults (N = 349), we tested a structural equation model linking SHLOC, perceived threat, efficacy beliefs, fear, and vaccination intentions. Results indicated that active SHLOC, reflecting beliefs in divine partnership in health, increased response efficacy and indirectly promoted booster intention and vaccine advocacy, whereas passive SHLOC, reflecting divine determinism, reduced self-efficacy and indirectly discouraged booster intention. Perceived threat was positively associated with fear, and efficacy beliefs emerged as the strongest predictors of booster intention. Mediation analyses supported serial pathways from message exposure to SHLOC to efficacy to intention, identifying spiritually grounded control beliefs as a culturally embedded mechanism in vaccine decision making. Findings suggest that faith-based engagement can function as either a protective or risk communication channel, depending on whether messages reinforce divine partnership or determinism. The study advances EPPM by identifying SHLOC as a culturally grounded antecedent to efficacy appraisal and offers implications for culturally responsive vaccine communication in Hispanic communities.

PubMedBMC cancer2026-11-11

High tissue factor (CD142) expression identifies a poor-prognosis subgroup of esophageal and esophagogastric junction adenocarcinoma.

Bedau Tillmann T, Zander Thomas T, Schlößer Hans H, Büttner Reinhard R et al.

Tissue Factor (TF/CD142) is an emerging antibody-drug conjugate (ADC) target, but its prevalence, prognostic value and molecular context in adenocarcinoma of the esophagus (EAC) and esophagogastric junction (EGJ) remain uncharacterized. TF immunohistochemistry was scored by H-score (0-300) on a tissue microarray of 1,120 resected EAC/EGJ adenocarcinomas (1996-2020); the 1,006 assessable primary tumors formed the analysis cohort. Tumors were graded TF-negative (≤ 10), TF-low (11-100) or TF-high (> 100) and related to clinicopathologic features, tissue compartment, neoadjuvant therapy, HER2, Claudin 18.2 (CLDN18.2), MET, mismatch-repair (MMR) status and overall survival. Primary tumors and lymph-node metastases were compared within patients. TF was positive in 486 of 1,006 tumors (48.3%) and high in 225 (22.4%). TF-positive tumors were more often pT3-4 (p < 0.001) and node-positive (p = 0.002), and TF grade agreed moderately between paired primary tumors and lymph-node metastases (n = 247; κ 0.57 at H-score > 100) without a systematic shift (p = 0.91). TF was independent of HER2 (p = 0.80) and MMR status (p = 0.14), inversely associated with CLDN18.2 (TF-high vs. TF-negative: 12.8% vs. 30.2%; p < 0.001) and positively with MET overexpression (8.6% vs. 1.0%; p < 0.001). Over a median follow-up of 67 months (749 patients, 428 deaths), the survival detriment was confined to TF-high tumors (median overall survival 19.3 vs. 36.8 and 42.2 months; p < 0.001). Adjusted for age, pT, nodal status and neoadjuvant therapy, TF-high remained adverse (HR 1.67, 95% CI 1.32-2.11; p < 0.001) whereas TF-low did not (HR 0.97; p = 0.83). The TF-high association held with TF as a continuous variable (HR 1.11 per 50 points; p < 0.001) and after adjustment for treatment era, margin, grade and lymphovascular invasion. TF positivity was similar in treatment-naïve and in residual post-neoadjuvant tumors (p = 0.89), but TF-high concentrated in poorly regressed tumors (29.2% vs. 11.6%; trend p < 0.001). TF is expressed in nearly half of EAC/EGJ adenocarcinomas and at high level in about one quarter, where it is independently associated with shorter overall survival. TF expression remains prevalent in residual tumors after neoadjuvant therapy and marks a compartment distinct from HER2 and CLDN18.2 and enriched for MET. TF-high is a candidate biomarker for prospective trials of TF-directed ADCs, in which its predictive value and the H-score > 100 threshold need testing.

PubMedInternational journal for equity in health2026-11-11

Reaching zero-dose children through the Big Catch-Up initiative in the Eastern Mediterranean Region.

Elmahdy Eman E, Mere Osama O, Farrukh Saadia S, Alyousfi Mohamad Nihad MN et al.

Routine immunization (RI) is one of the most effective public health interventions for reducing childhood morbidity and mortality. However, recent disruptions to RI have created immunity gaps in the Eastern Mediterranean Region (EMR), increasing the number of zero-dose (ZD) and under-immunized children, particularly in countries affected by conflict, displacement, service disruption, and ongoing vaccine-preventable disease outbreaks. The Big Catch-Up (BCU) initiative aimed to identify and vaccinate missed children, close immunity gaps, and strengthen RI systems. In the six Gavi-supported EMR countries included in this study (Afghanistan, Pakistan, Somalia, Sudan, Syria, and Yemen), implementation targeted children aged 12-59 months. This study assessed progress in reaching ZD children during BCU implementation in these six countries. A descriptive, multi-country programmatic analysis was conducted using quantitative and qualitative data from BCU quarterly reports covering implementation from Q4 2024 to Q1 2026. Additional data sources included World health Organization (WHO and United Nations Children's Fund (UNICEF) Estimates of National Immunization Coverage (WUENIC), Gavi-approved vaccine dose data, and UNICEF vaccine shipment data. Quantitative analysis summarized administered doses, zero-dose targets, BCU coverage, vaccine consumption, and performance by country and antigen among children aged 12-59 months. Age-disaggregated analyses were conducted for children aged 12-23 months and 24-59 months. Qualitative information from country reports on implementation successes, challenges, and lessons learned was summarized by country and thematic area. During the BCU implementation period, 3.5 million zero-dose children were reached with Penta1 across the six countries, representing 53% of the estimated cumulative population of 6.6 million ZD children. Of the 57 million Gavi-approved vaccine doses, 98% were shipped to countries, and 47.7 million doses were administered, equivalent to 84% of approved doses. Implementation success was supported by targeted identification of areas with high numbers of zero-dose children, integrated outreach, integration with other health services, and recruitment of vaccinators and deployment of community health workers. Key challenges included insecurity, population movement, inaccessible districts, community refusal, and limited community engagement. Substantial progress in reaching missed children was reported during BCU implementation in high-priority EMR countries. Lessons learned highlight the importance of integrating catch-up vaccination with RI, strengthening microplanning, ensuring timely vaccine supply and financing, improving community engagement, and institutionalizing catch-up vaccination.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MMR + varicella zoster vaccine